Abstract: Heart failure (HF) is a serious terminal stage of many cardiovascular diseases. Although great progress has been made in drug treatment, the prognosis is still not optimistic. Patients with heart failure receiving standard treatment still have high risk of death and rehospitalization. At present, several large randomized controlled studies have confirmed that the hypoglycemic drug sodium glucose cotransporter 2 (SGLT2) inhibitors have significant cardiovascular benefits, which can significantly reduce the risk of cardiovascular death and deterioration of heart failure in patients with heart failure whether or not they are accompanied by diabetes mellitus. In this paper, the cardiovascular benefits of SGLT2 inhibitors and the research and mechanism of the treatment of heart failure are discussed. It is expected that SGLT2 inhibitors can break the golden triangle of traditional heart failure treatment and realize the quadruple therapy combined with ACEI/ARB/ARNI, MRA and beta blockers.